Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Arsenault, Benoit J ^a   Barter, Philip ^b   DeMicco, David A ^c   Bao, Weihang ^c   Preston, Gregory M ^c   LaRosa, John C ^d   Grundy, Scott M ^e   Deedwania, Prakash ^f   Greten, Heiner ^g   Wenger, Nanette K ^h   Shepherd, James ⁱ   Waters, David D ^j   Kastelein, John J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HEART RESEARCH INSTITUTE   (Australia)

^c PFIZER INC   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j SAN FRANCISCO GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CYSTATIN C; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NEOPTERIN; OSTEOPONTIN; PHOSPHOLIPASE A2; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART ARREST; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CARDIOVASCULAR EVENT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; SMOKING; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CORONARY DISEASE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PROGNOSIS; TIME;

BIOMARKERS; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGNOSIS; TIME FACTORS;

EID: 84919632810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114519     Document Type: Article

References (29)

1. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
2. Packard RR, Libby P (2008) Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 54: 24-38.
3. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, et al. (2005) C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPICNorfolk prospective population study 1993-2003. Atherosclerosis 187: 415-422.
4. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, et al. (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20-28.
5. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
6. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR (2008) C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118: 2243-2251, 2244p following 2251.
7. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387-1397.
8. Sarwar N, Sattar N, Gudnason V, Danesh J (2007) Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. Eur Heart J 28: 2491-2497.
9. Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, et al. (2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 151: 496-507.
10. Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, et al. (2011) Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol 57: 63-69.
11. (2013) Retraction notice to "Prediction of cardiovascular events in statin-treated patients by lipid and non-lipid biomarkers". J Am Coll Cardiol 61: 1750.
12. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435.
13. Singh U, Devaraj S, Jialal I, Siegel D (2008) Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects th metabolic syndrome. Am J Cardiol 102: 321-325.
14. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, et al. (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. Jama 291: 1071-1080.
15. Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, et al. (2008) Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 30: 2298-2313.
16. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, et al. (2006) Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114: 281-288.
17. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373: 1175-1182.
18. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, et al. (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 120: 2177-2187.
19. Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, et al. (2007) N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 49: 311-319.
20. West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, et al. (2008) The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J 29: 923-931.
21. Scirica BM, Cannon CP, Sabatine MS, Jarolim P, Sloane S, et al. (2009) Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem 55: 265-273.
22. Meuwese MC, Trip MD, van Wissen S, van Miert JN, Kastelein JJ, et al. (2008) Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. Atherosclerosis 197: 916-921.
23. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, et al. (2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 55: 1209-1216.
24. Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, et al. (2012) Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res 53: 1000-1011.
25. Hopewell JC, Parish S, Offer A, Link E, Clarke R, et al. (2013) Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J 34: 982-992.
26. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301: 2331-2339.
27. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, et al. (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361: 2518-2528.
28. Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, et al. (2007) Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 115: 3071-3078.
29. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, et al. (2011) Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 60: 2379-2385.